DK3548053T3 - Bakteriofagsammensætninger, der omfatter respiratoriske antibakterielle fager, og fremgangsmåder til anvendelse deraf - Google Patents
Bakteriofagsammensætninger, der omfatter respiratoriske antibakterielle fager, og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK3548053T3 DK3548053T3 DK17838002.8T DK17838002T DK3548053T3 DK 3548053 T3 DK3548053 T3 DK 3548053T3 DK 17838002 T DK17838002 T DK 17838002T DK 3548053 T3 DK3548053 T3 DK 3548053T3
- Authority
- DK
- Denmark
- Prior art keywords
- bacterium
- subjects
- methods
- compositions including
- subject compositions
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title 1
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/40—Viruses, e.g. bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430113P | 2016-12-05 | 2016-12-05 | |
| PCT/PT2017/050028 WO2018106135A2 (en) | 2016-12-05 | 2017-12-04 | Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3548053T3 true DK3548053T3 (da) | 2022-05-09 |
Family
ID=61148457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17838002.8T DK3548053T3 (da) | 2016-12-05 | 2017-12-04 | Bakteriofagsammensætninger, der omfatter respiratoriske antibakterielle fager, og fremgangsmåder til anvendelse deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11672839B2 (da) |
| EP (1) | EP3548053B8 (da) |
| JP (1) | JP7154543B2 (da) |
| CN (1) | CN110691603B (da) |
| AU (1) | AU2017371484B2 (da) |
| BR (1) | BR112019011660A2 (da) |
| DK (1) | DK3548053T3 (da) |
| ES (1) | ES2912268T3 (da) |
| PT (1) | PT3548053T (da) |
| WO (1) | WO2018106135A2 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099316A1 (en) * | 2018-05-04 | 2019-11-07 | Locus Biosciences, Inc. | Methods and compositions for killing a target bacterium |
| US20210187046A1 (en) * | 2019-12-19 | 2021-06-24 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof |
| US12594312B2 (en) | 2020-04-27 | 2026-04-07 | Armata Pharmaceuticals, Inc. | Bacteriophage compositions for treating Pseudomonas infection |
| JP7584162B2 (ja) | 2020-05-22 | 2024-11-15 | ライセンテク カンパニー リミテッド | 新規なポリペプチド、融合ポリペプチド、およびこれを含むグラム陰性菌に対する抗生物質 |
| KR102224897B1 (ko) * | 2020-05-22 | 2021-03-08 | 주식회사 라이센텍 | 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제 |
| PL434485A1 (pl) * | 2020-06-26 | 2021-12-27 | Proteon Pharmaceuticals Spółka Akcyjna | Synergistyczna kompozycja fagów oraz sposób jej otrzymywania |
| AU2022247325A1 (en) * | 2021-03-30 | 2023-10-05 | Biomx Ltd. | Pseudomonas bacteriophage and uses thereof |
| US20220331381A1 (en) * | 2021-04-10 | 2022-10-20 | Intron Biotechnology, Inc. | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
| US20220323518A1 (en) * | 2021-04-10 | 2022-10-13 | Intron Biotechnology, Inc. | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
| US20220323517A1 (en) * | 2021-04-10 | 2022-10-13 | Intron Biotechnology, Inc. | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis |
| CN113025582B (zh) * | 2021-05-19 | 2022-04-15 | 吉林大学 | 一株肺炎克雷伯菌噬菌体及医用用途 |
| WO2023122608A1 (en) * | 2021-12-21 | 2023-06-29 | Adaptive Phage Therapeutics, Inc. | Assay for matching phage to bacteria |
| EP4265263A1 (en) * | 2022-04-19 | 2023-10-25 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Bacteriophage suitable for treating a bacterial infection caused by pseudomonas aeruginosa |
| EP4265264A1 (en) * | 2022-04-19 | 2023-10-25 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Bacteriophages suitable for treating a bacterial infection caused by klebsiella pneumoniae |
| EP4344399A1 (en) * | 2022-08-11 | 2024-04-03 | Phagelab Chile SPA | Bacteriophages and compositions thereof for controlling the growth of pseudomonas lundensis in meat products |
| EP4720263A1 (en) * | 2023-06-01 | 2026-04-08 | University of Florida Research Foundation, Incorporated | Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages |
| WO2025081186A1 (en) * | 2023-10-12 | 2025-04-17 | The Government of the United States, as represented by the Director of the Defense Health Agency | Bacteriophage cocktail to target diverse lineages of multidrug-resistant klebsiella pneumoniae |
| WO2025101001A1 (en) * | 2023-11-10 | 2025-05-15 | Microbiotix Co., Ltd. | Bacteriophage and bacteriophage cocktails and uses thereof |
| WO2025104708A1 (en) | 2023-11-16 | 2025-05-22 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Method for determining the susceptibility of bacteria to bacteriophages |
| CN117843804B (zh) * | 2023-12-29 | 2024-08-20 | 北京贝来药业有限公司 | 单域抗体串联分子及其序列、产品、制备和应用 |
| WO2025242868A1 (en) * | 2024-05-23 | 2025-11-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Phage composition |
| CN121622671A (zh) * | 2026-02-02 | 2026-03-10 | 山东省妇幼保健院 | 美罗培南或氨曲南与萘啶酸联用在制备抗菌药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| US8563504B2 (en) | 2008-10-10 | 2013-10-22 | Lusomedicamenta, S.A. | Antibacterial phage peptides and methods of use thereof |
| AU2010211456B2 (en) | 2009-02-06 | 2016-05-26 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| PT104837A (pt) | 2009-11-24 | 2011-05-24 | Technophage Investiga O E Desenvolvimento Em Biotecnologia S A | P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o |
| EP2536406A4 (en) * | 2010-02-03 | 2014-04-09 | Microbion Corp | WISMUT THIOLE AS ANTISEPTICA FOR BIOMEDICAL USE INCLUDING TREATMENT OF BACTERIAL BIOFILMS AND OTHER USES |
| TW201130497A (en) * | 2010-03-02 | 2011-09-16 | Univ Ishou | A new lytic phage specific to Klebsiella pneumoniae in medication prodection for treating Klebsiella pneumoniae infection related liver abscesses and bacteremia |
| CA3048783C (en) * | 2010-09-17 | 2022-05-24 | Tecnifar-Industria Tecnica Farmaceutica, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| RU2654596C2 (ru) * | 2012-03-19 | 2018-05-21 | Текнифар-Индустриа Текника Фармасеутика С.А. | Композиции коктейля, содержащие антибактериальные фаги, и способы их применения |
-
2017
- 2017-12-04 AU AU2017371484A patent/AU2017371484B2/en active Active
- 2017-12-04 BR BR112019011660-5A patent/BR112019011660A2/pt active Search and Examination
- 2017-12-04 ES ES17838002T patent/ES2912268T3/es active Active
- 2017-12-04 EP EP17838002.8A patent/EP3548053B8/en active Active
- 2017-12-04 WO PCT/PT2017/050028 patent/WO2018106135A2/en not_active Ceased
- 2017-12-04 PT PT178380028T patent/PT3548053T/pt unknown
- 2017-12-04 CN CN201780084644.5A patent/CN110691603B/zh active Active
- 2017-12-04 JP JP2019550541A patent/JP7154543B2/ja active Active
- 2017-12-04 DK DK17838002.8T patent/DK3548053T3/da active
- 2017-12-04 US US16/466,943 patent/US11672839B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020500935A (ja) | 2020-01-16 |
| CN110691603A (zh) | 2020-01-14 |
| WO2018106135A3 (en) | 2018-08-16 |
| CA3045284A1 (en) | 2018-06-14 |
| PT3548053T (pt) | 2022-05-04 |
| US20190290709A1 (en) | 2019-09-26 |
| EP3548053B1 (en) | 2022-03-02 |
| JP7154543B2 (ja) | 2022-10-18 |
| EP3548053A2 (en) | 2019-10-09 |
| ES2912268T3 (es) | 2022-05-25 |
| AU2017371484A1 (en) | 2019-06-20 |
| CN110691603B (zh) | 2024-01-30 |
| EP3548053B8 (en) | 2022-04-27 |
| BR112019011660A2 (pt) | 2019-10-22 |
| US11672839B2 (en) | 2023-06-13 |
| AU2017371484B2 (en) | 2022-09-15 |
| WO2018106135A2 (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3548053T3 (da) | Bakteriofagsammensætninger, der omfatter respiratoriske antibakterielle fager, og fremgangsmåder til anvendelse deraf | |
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
| DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3510157T3 (da) | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK4000608T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| DK3390430T3 (da) | Human immundefektvirus-antigener, vektorer, sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK2833899T3 (da) | Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner | |
| DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3644995T3 (da) | Deutererede domperidon-sammensætninger, fremgangsmåder og fremstilling | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3551619T3 (da) | Sammensætninger, der omfatter methylphenidat-prodrugs, fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3691649T3 (da) | Sammensætninger og fremgangsmåder til sårbehandling | |
| DK3357343T3 (da) | Fedtsammensætning og fremgangsmåde til fremstilling heraf | |
| DK3528787T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til fremstilling heraf |